GlassScriptPhysician profile
Steven P Chevalier
NPI 1104937481
$3,505.95
in general payments reported to CMS, 2019-2025
24 companies · $566 in 2025
The $566 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $273 · 2021: $331 · 2022: $585 · 2023: $588 · 2024: $779 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $638.53 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $423.00 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $366.47 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $353.20 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299.73 | 2019-2022 | |
| Pfizer INC. | $250.43 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $244.30 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $202.29 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $139.42 | 2021-2024 | Qelbree, Qelbree |
| Acadia Pharmaceuticals INC | $69.86 | 2024-2025 | Daybue |
| Sanofi-Aventis U.S. LLC | $69.77 | 2024-2025 | |
| Glaxosmithkline, LLC. | $66.29 | 2020-2023 | Bexsero |
| Astrazeneca Pharmaceuticals LP | $52.74 | 2023-2024 | Flumist Quadrivalent |
| Regeneron Healthcare Solutions, INC. | $51.80 | 2024 | Dupixent |
| Arbor Pharmaceuticals, INC. | $50.61 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $46.29 | 2019 | |
| Kaleo, INC. | $45.22 | 2019-2022 | |
| Genentech USA, INC. | $33.08 | 2019-2020 | |
| Seqirus USA INC | $29.73 | 2023-2024 | Fluad, Flucelvax, Flucelvax Quadrivalent |
| Abbott Laboratories | $20.98 | 2021 | |
| Shire North American Group INC | $15.44 | 2019 | |
| Adlon Therapeutics L.P. | $14.04 | 2021 | |
| Mission Pharmacal Company | $11.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Chevalier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.